PharmaTher Collaborates with MediSynergics to Develop Patented Ketamine Formulation for Pain Disorders and to Discover… May 27, 2021
PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease May 25, 2021
PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease May 17, 2021
PharmaTher Expands Patent Portfolio for Ketamine and Repurposing of Psychedelics with panaceAI™ Apr 27, 2021
PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the… Apr 20, 2021
